Global Botanical and Plant Derived Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Botanical and Plant Derived Drugs Market Research Report 2024
Botanical drugs are those drugs which are derived from medicinal plants. Plant derived drugs are combination of botanical as well as other approved drugs that contains plant materials, synthetic and semi synthetic substances. Botanical drugs consist of vegetable material, algae and macroscopic fungi. They are used in treatment of various diseases, such as central nervous system disorders, cardiovascular diseases, infectious diseases and respiratory diseases. Botanical drugs are available in various forms, such as pills, tablets, capsules and injections. Botanical drugs, such as aescin, adoniside, atropine and berberine, are derived from plants. These drugs are used as an important component of traditional medicine and therapies, such as homeopathy and ayurvedic medicines. Some of the major classes of plant drugs are terpenes, steroids, glycosides and phenols.
According to Mr Accuracy reports’s new survey, global Botanical and Plant Derived Drugs market is projected to reach US$ 37100 million in 2034, increasing from US$ 28140 million in 2024, with the CAGR of 3.6% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Botanical and Plant Derived Drugs market research.
Globally, increased usage of botanical drugs as an alternative to synthetic medicine and increasing prevalence of various chronic diseases are some of the major drivers for growth of botanical and plant derived drugs. In addition, low cost of botanical drugs and technological advancement in production procedure of botanical drugs are also supporting in growth of botanical and plant derived drugs market. However, stringent laws and regulations for approval of botanical drugs is a key restraint for botanical and plant derived drugs market.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Botanical and Plant Derived Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Abott Laboratories
Bayer Healthcare
Bionova
Bristol Myers
Curapharm
Segment by Type
Tablets
Capsules
Pills
Injections
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Botanical and Plant Derived Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Botanical and Plant Derived Drugs market is projected to reach US$ 37100 million in 2034, increasing from US$ 28140 million in 2024, with the CAGR of 3.6% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Botanical and Plant Derived Drugs market research.
Globally, increased usage of botanical drugs as an alternative to synthetic medicine and increasing prevalence of various chronic diseases are some of the major drivers for growth of botanical and plant derived drugs. In addition, low cost of botanical drugs and technological advancement in production procedure of botanical drugs are also supporting in growth of botanical and plant derived drugs market. However, stringent laws and regulations for approval of botanical drugs is a key restraint for botanical and plant derived drugs market.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Botanical and Plant Derived Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abott Laboratories
Bayer Healthcare
Bionova
Bristol Myers
Curapharm
Segment by Type
Tablets
Capsules
Pills
Injections
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Botanical and Plant Derived Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source